Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer

Skeletal involvement in metastatic castrate-resistant prostate cancer (mCRPC) is common and results in significant morbidity and mortality. The interaction of prostate cancer with the bone microenvironment contributes to progression of cancer in the bone leading to skeletal-related events (SREs). Studies aimed at targeting the bone have been carried out over the recent years. Bisphosphonates ar...

Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

BACKGROUND Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. METHODS In this double-blind, placebo-co...

Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.

BACKGROUND Metastatic castration-resistant prostate cancer (mCRPC) most commonly metastasizes to the bone, and less commonly to nonosseous sites (eg, lymph nodes, liver, lung). With new therapies extending survival in mCRPC, it was hypothesized that the pattern of metastases is changing over time. The pattern of metastatic disease was evaluated in men with mCRPC, as reported in baseline charact...

Cost Effectiveness of radium-223 (Xofigo) for castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases

The HSE has asked the National Centre for Pharmacoeconomics (NCPE) to evaluate the manufacturer’s (Bayer) economic dossier on the cost effectiveness of radium223. The NCPE uses a decision framework to systematically assess whether a technology is cost effective. This includes clinical effectiveness and health related quality of life benefits that the new treatment may provide and whether the co...